American Society of Gene & Cell Therapy’s Post

Looking forward to this discussion tomorrow at #ASGCT2024!

May is Melanoma Awareness Month. Check out this conversation with three authors of a recent POT1 study. Come for the research recap, but stay for the discussion of gene disease validity, limited evidence genes, and the importance of clinical utility when designing and choosing multigene panels. #genetictesting #POT1 #MelanomaAwareness https://hubs.ly/Q02z5sNG0

Research Article Clinical Improvement in Early-Onset Interstitial Lung Disease Using Rituximab in Children With Antimelanoma Differentiation-Associated Gene 5–Positive Juvenile Dermatomyositis 📰 https://lnkd.in/gwjXHjzE #interstitiallungdisease #juveniledermatomyositis

Great to be a part on some engaging discussions on the recent USP Draft Chapter <1040> Quality Considerations of Plasmid DNA as a starting material for cell and gene therapies. In response to this draft chapter, we brought together 15 subject matter experts across 9 organizations to undertake a review of the proposed document. Feed-back has now been provided to USP. We welcome this much needed draft chapter to provide clarity on the quality considerations of plasmid DNA as a starting material and look forward to hearing more on this. Watch this space! #genetherapy #genetherapies #celltherapy #plasmidDNA #usp

Prostate Cancer Awareness Month is nearly over, prompting the question "What Can I Do?" Here are key factors to consider to stay informed and proactive: - Race and Family History - Aging and Diet - Gene Changes and Chemical Exposure #prostatecancerawarenessmonth #raisingawareness #solutionfocused #endprostatecancer

Today, we proudly join the global community in raising awareness for Rare Disease Day. At Kyfora Bio, we are dedicated to providing innovative solutions to pioneer advanced cell and gene therapies that offer hope to those affected by rare diseases. Our transfection reagents are used in several clinical trials globally. Together, let's continue to break barriers, drive research, and transform lives.    Read a few examples of how our transfection reagents are used in rare disease research:     Farby's Disease: https://lnkd.in/ebxbiTRH     Hemophilia: https://lnkd.in/e4wPw3t7     Huntington's Disease: https://lnkd.in/ePah_N-6     Stargardt Disease: https://lnkd.in/eQsjE6KC     #rarediseaseday #kyforabio #gene therapy #celltherapy #bioprocessing 

Today, we raise awareness about Cystic Fibrosis (CF) and the CFTR gene, whose mutations cause this genetic disease affecting 70,000+ people globally. Key Facts: 🔬 There are over 2,000 CFTR mutations, with ΔF508 being the most common. 💊 CFTR modulator treatments are improving lung function and quality of life. 💪 Many CF patients now live into their 40s or beyond. 💡 Newborn screening helps detect CF early for better outcomes. Let’s support research and work toward a better future for people with CF! #CFTRWorldDay #CysticFibrosis #ResearchMatters #HealthcareInnovation

Get your weekly biopharma news fix at the BioSpace podcast "The Weekly." This week, you can catch up on what's hot at #ASGCT. #biopharma #theweekly #biospace

Hurry up, time is running out! Spread the word if you know someone affected by Sickle Cell Disease! Don't miss our upcoming webinar with Teresa Ginger Davis from Sickle Cell Thalassemia Patients Network and Farah Gaillard MSN, RN, FNP from Vertex Pharmaceuticals. They will be discussing the patient perspective on gene therapy for Sickle Cell Disease. We look forward to sharing this important conversation with you. https://bit.ly/3vH4p3O #sicklecelldisease #raredisease #patientawareness

Read more about focusing on developing a CRISPR-gene editing strategy for valosin-containing Containing Protein (VCP) disease.